Last reviewed · How we verify
Iopamidol 370
At a glance
| Generic name | Iopamidol 370 |
|---|---|
| Also known as | Isovue 370 |
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (PHASE1)
- Adenosine Contrast CorrELations in Evaluating RevAscularizaTION (PHASE4)
- Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA (NA)
- Kidney Damage in Patients With Moderate Fall in eGFR (PHASE4)
- Myocardial Stress Perfusion Imaging With Dual Source CT (NA)
- Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure (PHASE2)
- Comparison of Contrast Agents During CT Angiography (NA)
- Thoracoabdominal Arortic CTA Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopamidol 370 CI brief — competitive landscape report
- Iopamidol 370 updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI